UPDATE 1-Amgen antibody shows promise in myeloma trial, gets FDA fast track


Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer. FILE PHOTO - An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013 file photo.



from Biotech News